GSK takes equity stake in Spero, and global rights to tebipenem except for certain Asian markets. Merck KGaA gets rights to Nerviano’s next-generation PARP inhibitor for cancer.

Dr Reddy’s is the first of six generics firms to challenge Intercept’s Ocaliva patents to reach a settlement, and will be able to market its product in the US from 2035 onward.

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

With new antibiotics a rare commodity, persistently inadequate reimbursement for innovations and worthy but often piecemeal pilots, antimicrobial resistance has quietly risen to become a factor in well over a million deaths annually. Now that COVID-19 is not the all-encompassing threat to health it was until fairly recently, AMR is once again moving towards the center of attention. But properly funded actions and mindset changes are needed.